In this blog we discuss PBMC stimulation assays and the ways in which we leverage these assays at Cellomatics to better understand immunity, guide therapy development, and contribute to global scientific knowledge.
Peripheral blood mononuclear cells, or PBMCs, are a cornerstone of immunology research. These cells, which include lymphocytes such as T-cells, B-cells, and natural killer cells, along with monocytes, provide a window into the human immune system. By studying how PBMCs respond under various conditions, researchers can gain insights into immune function, disease mechanisms, and therapeutic potential. At Cellomatics, we frequently employ PBMC stimulation assays to better understand complex immune responses, and I think their role in modern immunology cannot be overstated.
PBMC stimulation assays are designed to activate these immune cells in vitro using specific stimuli. These stimuli can range from pathogens like bacteria or viruses, to synthetic molecules such as lipopolysaccharides, or even therapeutic agents. The goal is to mimic how the immune system would react in a real biological scenario, allowing researchers to measure cytokine production, proliferation, surface marker expression, or other functional responses. Essentially, these assays allow us to “ask” immune cells how they react, and to study the answers in a controlled, reproducible way.
One of the key advantages of PBMC stimulation assays is their relevance to human biology. Unlike animal models, PBMCs are derived from human donors, so the results can more accurately reflect human immune responses. Of course, variability between donors is something to account for—immune responses are highly individual, influenced by genetics, age, health status, and environmental exposures. But this variability is also valuable, because it provides insights into why patients respond differently to infections, vaccines, or therapies.
In drug development, PBMC assays are used to assess immunotoxicity and immunogenicity. For example, when developing a new biologic therapy, researchers can expose PBMCs to the drug to determine whether it triggers excessive immune activation, which could lead to adverse effects. Conversely, these assays can be used to test vaccine candidates, assessing whether they induce the desired immune response without harmful side effects. At Cellomatics, we use PBMC stimulation assays alongside high-throughput cytokine profiling to generate detailed immune signatures that help guide experimental design and therapeutic evaluation.
PBMC assays are also invaluable for understanding disease mechanisms. In autoimmune disorders, researchers can compare PBMC responses from affected patients with healthy controls, revealing dysregulated pathways that contribute to disease pathology. In infectious diseases, these assays help elucidate how pathogens manipulate immune responses and identify potential therapeutic targets. Even in cancer research, PBMC assays can inform immunotherapy strategies by evaluating how immune cells react to tumour antigens or checkpoint inhibitors. The applications are surprisingly broad, and the insights often translate directly to clinical relevance.
One interesting aspect is the ability to combine PBMC assays with other advanced models. For instance, co-culturing PBMCs with organoids or tissue-on-chip systems allows researchers to study immune-tissue interactions in more physiologically relevant contexts. This is particularly useful for understanding immune responses in organs like the lung, liver, or gut, where tissue architecture and microenvironment significantly influence cell behaviour. These integrated approaches can reveal subtleties that simpler assays might miss, offering a richer, more holistic picture of immune function.
Data analysis is critical in PBMC research. Stimulated cells can produce a vast array of cytokines and other biomarkers, and interpreting these results requires careful statistical and computational methods. Machine learning tools are increasingly used to identify patterns, predict outcomes, or classify immune responses. While these tools are powerful, they are best employed alongside human expertise—biology is rarely straightforward, and patterns identified computationally must be interpreted in context.
Looking forward, PBMC stimulation assays will continue to play a pivotal role in immunology. Advances in single-cell analysis, high-dimensional flow cytometry, and multiplex cytokine detection are making it possible to dissect immune responses at unprecedented resolution. Integrating these technologies with patient-derived models and computational analytics will likely enhance predictive power, accelerate therapeutic development, and provide deeper insights into immune system function.
Ultimately, PBMC stimulation assays represent more than a laboratory technique—they are a lens through which we can observe the dynamic, nuanced, and often unpredictable behaviour of the human immune system. At Cellomatics, we are committed to leveraging these assays to better understand immunity, guide therapy development, and contribute to global scientific knowledge. It’s a reminder that even as we advance technologically, the human immune system remains one of the most complex and fascinating systems to study, and every insight we gain brings us closer to improving patient outcomes.
Visit our PBMC assays page to find out more about the work we do at Cellomatics.
